No abstract

Background: Increased expression of the astroglial Ca 2+ -binding protein S100B has been observed in various neurodegenerative diseases and also seems to play a role in the unfolding of pathophysiological events at early stages of Alzheimer's disease (AD). Objective: To examine the association of cerebrospinal fluid (CSF) levels of S100B with 1) established CSF core biomarkers total tau (tau), hyperphosphorylated tau (p-tau), and amyloid ␤ 1-42 (A␤ 1-42 ) as well as neuron-specific enolase (NSE) CSF levels and 2) cognition in early AD and mild cognitive impairment (MCI) due to AD (MCI-AD). Methods: Retrospective study assessing 49 pooled charts of Memory Clinic and inpatients diagnosed with AD (N = 26) and MCI-AD (N = 23) according to the National Institute of Aging and Alzheimer's Disease Association (NIA-AA) criteria. Neuropsychological testing was performed with the Consortium to Establish a Registry for AD (CERAD)-Plus battery. Results: CSF levels of S100B correlated with NSE, but not the other CSF parameters. Stepwise multiple linear regression, adjusted for age, sex, and educational level, revealed that only increased CSF S100B was independently associated with lower CERAD-Plus total and Mini-Mental Status Examination scores together with poorer performance in wordlist learning (delayed recall and overall performance). We found no independent associations with other CSF biomarkers or cognitive domains. Conclusion: Our data suggest that CSF S100B may have a diagnostic value particularly at early stages of AD reflecting the significance of neuroinflammatory/astroglial processes. Thus, CSF S100B may complement the established array of available AD biomarkers to improve early stage diagnosis.

No abstract

Aim: Against the background of the rising number of elderly people being incarcerated and the rare data on this special subgroup, the aim of our study was to collect first empirical data on the affective state of elderly prisoners in North Rhine Westphalia, Germany. Methods: Data were collected in nine German prisons. We included elderly prisoners from pretrial prevention, penal sentences, open enforcement, preventive detention and from special detention units for elderly inmates. For the evaluation of the affective state, we used the Patient Health Questionnaire (PHQ-9). Sociodemographic and crime-related characteristics were documented. Findings: In total, n=116 prisoners (91.4% male) were included. The age ranged from 53 to 91 years (65.6±6.3 years). In our sample, 48% reported at least mild depressive symptoms, which is a significantly higher prevalence of depressive symptomatology than in the general population aged 60 years and older. Differences were found with regard to the type of detention, as prisoners in open enforcement showed significantly less symptoms compared to those in pretrial prevention and preventive detention. The participants reported in general more somatic symptoms as sleep disturbances and fatigue compared to mood items as feelings of sadness. Originality: It is the first study assessing the affective state of older prisoners in Germany. The high rate of depressive symptoms in our sample is in line with findings from international studies underlining the need for adequate diagnostics and therapy. In addition, in a previous study depression was indirectly linked with a greater risk of re-incarceration, fortifying the need for successful treatment of depression in prison both for the individuum and for society.

No abstract